The virus-induced signaling adaptor molecule enhances DNA-raised immune protection against H5N1 influenza virus infection in mice

Vaccine

Volumn 29, Issue 14, 2011, Pages 2561-2567

  Luo, Mengcheng ^a   Qu, Xiao ^a   Pan, Ruangang ^a   Zhu, Dandan ^a   Zhang, Yuan ^a   Wu, Jianguo ^a   Pan, Zishu ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

DNA vaccines; Genetic adjuvant; H5N1 influenza virus; TRIF; VISA

Indexed keywords

DNA VACCINE; HEMAGGLUTININ; INFLUENZA VACCINE; MEMBRANE PROTEIN; NUCLEOPROTEIN; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; UNCLASSIFIED DRUG; VIRUS INDUCED SIGNALING ADAPTOR MOLECULE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; DNA IMMUNIZATION; FEMALE; IMMUNE RESPONSE; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADAPTOR PROTEINS, VESICULAR TRANSPORT; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; RNA-BINDING PROTEINS; VACCINES, DNA; VIRAL CORE PROTEINS;

EID: 79952244799     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.01.060     Document Type: Article

References (72)

1. Claas E.C., Osterhaus A.D., van Beek R., De Jong J.C., Rimmelzwaan G.F., Senne D.A., et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998, 351(9101 (February)):472-477.
2. Li C., Hatta M., Nidom C.A., Muramoto Y., Watanabe S., Neumann G., et al. Reassortment between avian H5N1 and human H3N2 influenza viruses creates hybrid viruses with substantial virulence. Proc Natl Acad Sci USA 2010, 107(10):4687.
3. Stephenson I., Nicholson K.G., Wood J.M., Zambon M.C., Katz J.M. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis 2004, 4(8 (August)):499-509.
4. Gillim-Ross L., Subbarao K. Emerging respiratory viruses: challenges and vaccine strategies. Clin Microbiol Rev 2006, 19(4 (October)):614-636.
5. Palese P., Garcia-Sastre A. Influenza vaccines: present and future. J Clin Invest 2002, 110(1 (July)):9-13.
6. Szucs T.D., Ruef C., Muller D., Sokolovic E., Beeler I., Ostermayer W. The economic impact of influenza in a university hospital setting. Infect Control Hosp Epidemiol 2001, 22(8 (August)):472-474.
7. Ito T., Kawaoka Y. Host-range barrier of influenza A viruses. Vet Microbiol 2000, 74(1-2 (May)):71-75.
8. Donnelly J.J., Friedman A., Martinez D., Montgomery D.L., Shiver J.W., Motzel S.L., et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med 1995, 1(6 (June)):583-587.
9. Donnelly J.J., Ulmer J.B., Shiver J.W., Liu M.A. DNA vaccines. Annu Rev Immunol 1997, 15:617-648.
10. Raz E., Carson D.A., Parker S.E., Parr T.B., Abai A.M., Aichinger G., et al. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci USA 1994, 91(20 (September)):9519-9523.
11. Wang B., Dang K., Agadjanyan M.G., Srikantan V., Li F., Ugen K.E., et al. Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 at a mucosal site. Vaccine 1997, 15(8 (June)):821-825.
12. Robinson H.L., Hunt L.A., Webster R.G. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine 1993, 11(9):957-960.
13. Donnelly J.J., Wahren B., Liu M.A. DNA vaccines: progress and challenges. J Immunol 2005, 175(2 (July)):633-639.
14. Babiuk L.A., Pontarollo R., Babiuk S., Loehr B. Induction of immune responses by DNA vaccines in large animals. Vaccine 2003, 21(7-8):649-658.
15. Luckay A., Sidhu M.K., Kjeken R., Megati S., Chong S.Y., Roopchand V., et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 2007, 81(10 (May)):5257-5269.
16. Widera G., Austin M., Rabussay D., Goldbeck C., Barnett S.W., Chen M., et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000, 164(9 (May)):4635-4640.
17. Li Z., Howard A., Kelley C., Delogu G., Collins F., Morris S. Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences. Infect Immun 1999, 67(9 (September)):4780-4786.
18. Luo M., Tao P., Li J., Zhou S., Guo D., Pan Z. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice. J Virol Methods 2008, 154(1-2 (December)):121-127.
19. Liang R., van den Hurk J.V., Landi A., Lawman Z., Deregt D., Townsend H., et al. DNA prime protein boost strategies protect cattle from bovine viral diarrhea virus type 2 challenge. J Gen Virol 2008, 89(Pt 2 (February)):453-466.
20. Larsen D.L., Dybdahl-Sissoko N., McGregor M.W., Drape R., Neumann V., Swain W.F., et al. Coadministration of DNA encoding interleukin-6 and hemagglutinin confers protection from influenza virus challenge in mice. J Virol 1998, 72(2 (February)):1704-1708.
21. Loudon PT, Yager EJ, Lynch DT, Narendran A, Stagnar C, Franchini AM, et al. GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates. PLoS One;5(6):e11021.
22. Chow Y.H., Huang W.L., Chi W.K., Chu Y.D., Tao M.H. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J Virol 1997, 71(1 (January)):169-178.
23. Schadeck E.B., Sidhu M., Egan M.A., Chong S.Y., Piacente P., Masood A., et al. A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine 2006, 24(21 (May)):4677-4687.
24. Su B., Wang J., Wang X., Jin H., Zhao G., Ding Z., et al. The effects of IL-6 and TNF-alpha as molecular adjuvants on immune responses to FMDV and maturation of dendritic cells by DNA vaccination. Vaccine 2008, 26(40 (September)):5111-5122.
25. Wang X., Zhang X., Kang Y., Jin H., Du X., Zhao G., et al. Interleukin-15 enhance DNA vaccine elicited mucosal and systemic immunity against foot and mouth disease virus. Vaccine 2008, 26(40 (September)):5135-5144.
26. Durbin J.E., Fernandez-Sesma A., Lee C.K., Rao T.D., Frey A.B., Moran T.M., et al. Type I IFN modulates innate and specific antiviral immunity. J Immunol 2000, 164(8 (April)):4220-4228.
27. Levy D.E., Garcia-Sastre A. The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev 2001, 12(2-3 (June-September)):143-156.
28. Levy D.E., Marie I.J. RIGging an antiviral defense-it's in the CARDs. Nat Immunol 2004, 5(7 (July)):699-701.
29. Theofilopoulos A.N., Baccala R., Beutler B., Kono D.H. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005, 23:307-336.
30. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004, 5(10 (October)):987-995.
31. Le Bon A., Tough D.F. Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 2002, 14(4 (August)):432-436.
32. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413(6857 (October)):732-738.
33. Han K.J., Su X., Xu L.G., Bin L.H., Zhang J., Shu H.B. Mechanisms of the TRIF-induced interferon-stimulated response element and NF-kappaB activation and apoptosis pathways. J Biol Chem 2004, 279(15 (April)):15652-15661.
34. Oshiumi H., Matsumoto M., Funami K., Akazawa T., Seya T. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nat Immunol 2003, 4(2 (February)):161-167.
35. Yamamoto M., Sato S., Hemmi H., Hoshino K., Kaisho T., Sanjo H., et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003, 301(5633 (August)):640-643.
36. Yoneyama M., Kikuchi M., Natsukawa T., Shinobu N., Imaizumi T., Miyagishi M., et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004, 5(7 (July)):730-737.
37. Andrejeva J., Childs K.S., Young D.F., Carlos T.S., Stock N., Goodbourn S., et al. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc Natl Acad Sci USA 2004, 101(49 (December)):17264-17269.
38. Xu L.G., Wang Y.Y., Han K.J., Li L.Y., Zhai Z., Shu H.B. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol Cell 2005, 19(6 (September)):727-740.
39. Kawai T., Takahashi K., Sato S., Coban C., Kumar H., Kato H., et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol 2005, 6(10 (October)):981-988.
40. Meylan E., Curran J., Hofmann K., Moradpour D., Binder M., Bartenschlager R., et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005, 437(7062 (October)):1167-1172.
41. Seth R.B., Sun L., Ea C.K., Chen Z.J. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 2005, 122(5 (September)):669-682.
42. Takeshita F., Tanaka T., Matsuda T., Tozuka M., Kobiyama K., Saha S., et al. Toll-like receptor adaptor molecules enhance DNA-raised adaptive immune responses against influenza and tumors through activation of innate immunity. J Virol 2006, 80(13 (July)):6218-6224.
43. Wan C., Yi L., Yang Z., Yang J., Shao H., Zhang C., et al. The Toll-like receptor adaptor molecule TRIF enhances DNA vaccination against classical swine fever. Vet Immunol Immunopathol 2010, 137(15(September)):47-53.
44. Pashine A., Valiante N.M., Ulmer J.B. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005, 11(4 Suppl. (April)):S63-S68.
45. Sasaki S., Amara R.R., Yeow W.S., Pitha P.M., Robinson H.L. Regulation of DNA-raised immune responses by cotransfected interferon regulatory factors. J Virol 2002, 76(13 (July)):6652-6659.
46. Kwissa M., Amara R.R., Robinson H.L., Moss B., Alkan S., Jabbar A., et al. Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus. J Exp Med 2007, 204(11 (October)):2733-2746.
47. Tao P., Luo M., Zhu D., Qu S., Yang Z., Gao M., et al. Virus-like particle vaccine comprised of the HA, NA, and M1 proteins of an avian isolated H5N1 influenza virus induces protective immunity against homologous and heterologous strains in mice. Viral Immunol 2009, 22(4 (July)):273-281.
48. Tao P., Luo M., Pan R., Ling D., Zhou S., Tien P., et al. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice. Antiviral Res 2009, 81(3 (March)):253-260.
49. Bin L.H., Xu L.G., Shu H.B. TIRP, a novel Toll/interleukin-1 receptor (TIR) domain-containing adapter protein involved in TIR signaling. J Biol Chem 2003, 278(27 (July)):24526-24532.
50. Luo X., Ling D., Li T., Wan C., Zhang C., Pan Z. Classical swine fever virus Erns glycoprotein antagonizes induction of interferon-beta by double-stranded RNA. Can J Microbiol 2009, 55(6 (June)):698-704.
51. Wang S., Taaffe J., Parker C., Solorzano A., Cao H., Garcia-Sastre A., et al. Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. J Virol 2006, 80(23 (December)):11628-11637.
52. Webster R., Cox N., Stohr K. WHO Manual on Animal Influenza Diagnosis and Surveillance 2002.
53. Falk K., Rotzschke O., Stevanovic S., Jung G., Rammensee H.G. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991, 351(6324 (May)):290-296.
54. Fu T.M., Friedman A., Ulmer J.B., Liu M.A., Donnelly J.J. Protective cellular immunity: cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization. J Virol 1997, 71(4 (April)):2715-2721.
55. Bodmer H.C., Pemberton R.M., Rothbard J.B., Askonas B.A. Enhanced recognition of a modified peptide antigen by cytotoxic T cells specific for influenza nucleoprotein. Cell 1988, 52(2 (January)):253-258.
56. Sherman L.A., Burke T.A., Biggs J.A. Extracellular processing of peptide antigens that bind class I major histocompatibility molecules. J Exp Med 1992, 175(5 (May)):1221-1226.
57. Webster R.G., Fynan E.F., Santoro J.C., Robinson H. Protection of ferrets against influenza challenge with a DNA vaccine to the haemagglutinin. Vaccine 1994, 12(16 (December)):1495-1498.
58. Ohba K., Yoshida S., Zahidunnabi Dewan M., Shimura H., Sakamaki N., Takeshita F., et al. Mutant influenza A virus nucleoprotein is preferentially localized in the cytoplasm and its immunization in mice shows higher immunogenicity and cross-reactivity. Vaccine 2007, 25(21 (May)):4291-4300.
59. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259(5102 (March)):1745-1749.
60. Nimal S., Heath A.W., Thomas M.S. Enhancement of immune responses to an HIV gp120 DNA vaccine by fusion to TNF alpha cDNA. Vaccine 2006, 24(16 (April)):3298-3308.
61. Tsuji T., Hamajima K., Fukushima J., Xin K.Q., Ishii N., Aoki I., et al. Enhancement of cell-mediated immunity against HIV-1 induced by coinnoculation of plasmid-encoded HIV-1 antigen with plasmid expressing IL-12. J Immunol 1997, 158(8 (April)):4008-4013.
62. Yoon H.A., Aleyas A.G., George J.A., Park S.O., Han Y.W., Lee J.H., et al. Cytokine GM-CSF genetic adjuvant facilitates prophylactic DNA vaccine against pseudorabies virus through enhanced immune responses. Microbiol Immunol 2006, 50(2):83-92.
63. Nimal S., McCormick A.L., Thomas M.S., Heath A.W. An interferon gamma-gp120 fusion delivered as a DNA vaccine induces enhanced priming. Vaccine 2005, 23(30 (June)):3984-3990.
64. Kaisho T., Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 2002, 1589(1 (February)):1-13.
65. James C.M., Abdad M.Y., Mansfield J.P., Jacobsen H.K., Vind A.R., Stumbles P.A., et al. Differential activities of alpha/beta IFN subtypes against influenza virus in vivo and enhancement of specific immune responses in DNA vaccinated mice expressing haemagglutinin and nucleoprotein. Vaccine 2007, 25(10 (February)):1856-1867.
66. Sumida S.M., McKay P.F., Truitt D.M., Kishko M.G., Arthur J.C., Seaman M.S., et al. Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. J Clin Invest 2004, 114(9 (November)):1334-1342.
67. Darquet A.M., Rangara R., Kreiss P., Schwartz B., Naimi S., Delaere P., et al. Minicircle: an improved DNA molecule for in vitro and in vivo gene transfer. Gene Ther 1999, 6(2 (February)):209-218.
68. Fonseca C.T., Pacifico L.G., Barsante M.M., Rassi T., Cassali G.D., Oliveira S.C. Co-administration of plasmid expressing IL-12 with 14-kDa Schistosoma mansoni fatty acid-binding protein cDNA alters immune response profiles and fails to enhance protection induced by Sm14 DNA vaccine alone. Microbes Infect 2006, 8(9-10 (August)):2509-2516.
69. Epstein S.L., Stack A., Misplon J.A., Lo C.Y., Mostowski H., Bennink J., et al. Vaccination with DNA encoding internal proteins of influenza virus does not require CD8(+) cytotoxic T lymphocytes: either CD4(+) or CD8(+) T cells can promote survival and recovery after challenge. Int Immunol 2000, 12(1 (January)):91-101.
70. Yewdell J.W., Hill A.B. Viral interference with antigen presentation. Nat Immunol 2002, 3(11 (November)):1019-1025.
71. Doherty P.C., Turner S.J., Webby R.G., Thomas P.G. Influenza and the challenge for immunology. Nat Immunol 2006, 7(5 (May)):449-455.
72. Deliyannis G., Jackson D.C., Ede N.J., Zeng W., Hourdakis I., Sakabetis E., et al. Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus. J Virol 2002, 76(9 (May)):4212-4221.